

HR 2113

Prescription Drug STAR Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 8, 2019

Current Status: Placed on the Union Calendar, Calendar No. 571.

Latest Action: Placed on the Union Calendar, Calendar No. 571. (Dec 24, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/2113>

Sponsor

Name: Rep. Neal, Richard E. [D-MA-1]

Party: Democratic • **State:** MA • **Chamber:** House

Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Brady, Kevin [R-TX-8]	R · TX		Apr 8, 2019
Rep. Finkenauer, Abby [D-IA-1]	D · IA		Apr 15, 2019
Rep. Van Drew, Jefferson [D-NJ-2]	D · NJ		Apr 15, 2019
Rep. Houlahan, Chrissy [D-PA-6]	D · PA		Apr 18, 2019
Rep. Raskin, Jamie [D-MD-8]	D · MD		Apr 29, 2019
Rep. McAdams, Ben [D-UT-4]	D · UT		May 2, 2019
Rep. Underwood, Lauren [D-IL-14]	D · IL		May 7, 2019
Rep. Slotkin, Elissa [D-MI-8]	D · MI		May 15, 2019
Rep. Lipinski, Daniel [D-IL-3]	D · IL		May 22, 2019
Rep. Lofgren, Zoe [D-CA-19]	D · CA		Jun 13, 2019
Rep. Amodei, Mark E. [R-NV-2]	R · NV		Nov 5, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 9, 2019
Ways and Means Committee	House	Referred to	Apr 8, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 2115	Related bill	Oct 29, 2019: Received in the Senate and Read twice and referred to the Committee on Finance.
116 S 2051	Related bill	Jun 28, 2019: Read twice and referred to the Committee on Finance.
116 HR 2064	Related bill	May 21, 2019: Subcommittee Hearings Held.
116 HR 2069	Related bill	May 21, 2019: Subcommittee Hearings Held.
116 HR 2087	Related bill	May 21, 2019: Subcommittee Hearings Held.

Summary (as of Dec 24, 2020)

Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or the Prescription Drug STAR Act

This bill establishes requirements for prescription drug manufacturers to provide certain information about pricing, discounts, and product samples of applicable drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to annually determine whether there are price increases of a certain threshold for outpatient prescription drugs covered under Medicare, excluding low-cost drugs.

Manufacturers must provide HHS with an explanation for drug prices that (1) cumulatively increase by at least 10% or \$10,000 over one year; (2) cumulatively increase by at least 25% or \$25,000 over three years; or (3) are at least \$26,000 annually, per individual, if first covered by Medicare during the applicable year. The manufacturer must explain the role of the factors contributing to such prices and other relevant information, including manufacturing costs, marketing costs, and revenue.

Additionally, drug manufacturers must provide HHS with aggregate data related to product samples of drugs, devices, biologic products, and medical supplies given to hospitals, physicians, or other medical professionals during the previous calendar year, beginning in 2023.

The bill further requires HHS to make publicly available the information related to drug discounts, rebates, and price concessions that is provided annually to HHS by group health plans. Drug manufacturers also must report to HHS certain sales information for drugs available under Medicare for which the manufacturer does not have a rebate agreement in place.

The bill requires HHS to study and report on trends concerning inpatient hospital drug costs.

Actions Timeline

- Dec 24, 2020: Reported (Amended) by the Committee on Ways and Means. H. Rept. 116-688, Part I.
- Dec 24, 2020: Committee on Energy and Commerce discharged.
- Dec 24, 2020: Placed on the Union Calendar, Calendar No. 571.
- Apr 9, 2019: Committee Consideration and Mark-up Session Held.
- Apr 9, 2019: Ordered to be Reported by Voice Vote.
- Apr 9, 2019: Referred to the Subcommittee on Health.
- Apr 8, 2019: Introduced in House
- Apr 8, 2019: Referred to the Subcommittee on Health.
- Apr 8, 2019: Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.